Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
Please always quote using this URN: urn:nbn:de:bvb:20-opus-288213
- Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.…
Author: | Natalia Kirsten, Frenz Ohm, Kathrin Gehrdau, Gefion Girbig, Brigitte Stephan, Nesrine Ben-Anaya, Andreas Pinter, Falk G. Bechara, Dagmar Presser, Christos C. Zouboulis, Matthias Augustin |
---|---|
URN: | urn:nbn:de:bvb:20-opus-288213 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie |
Language: | English |
Parent Title (English): | Life |
ISSN: | 2075-1729 |
Year of Completion: | 2022 |
Volume: | 12 |
Issue: | 10 |
Article Number: | 1518 |
Source: | Life (2022) 12:10, 1518. https://doi.org/10.3390/life12101518 |
DOI: | https://doi.org/10.3390/life12101518 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | TNF alpha; adalimumab; adverse drug reaction; biologics; biosimilar; drug effectiveness; hidradenitis suppurativa; registry; switching |
Release Date: | 2023/08/24 |
Date of first Publication: | 2022/09/29 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |